The immuno-oncology field is a relatively new therapeutic avenue, and drugs targeting neoantigens, either directly or indirectly, have shown strong antitumor efficacy in the clinic. However, the identification of neoantigens and production of peptides are major bottlenecks in the development of personalized and universal cancer immunotherapies.

Learn how these neoantigen epitopes can be identified and how peptides can be used during various stages in the development of therapeutics to generate more effective and durable treatments. Cayman’s immunopeptidome profiling techniques to discover neoantigen candidates through functional screening of MHC-bound neoepitopes is discussed. Key considerations in experimental design for optimal peptide identification are presented.

Hosted by Nature Research in collaboration with GenScript.

Learn more about our Immunopeptidome Profiling Services: [ Ссылка ]

свернуть